Biliary tract cancers: current knowledge, clinical candidates and future challenges

Noor-Ul-Ain Tariq, Mairead Mcnamara, Juan Valle

Research output: Contribution to journalArticlepeer-review


Biliary tract cancers (BTC) are rare with a poor prognosis. Due to the advent of genomic sequencing, new data has emerged regarding the molecular make up of this disease. To add to the complexity, the various subtypes also harbour a varied genetic composition. The commonly-mutated genes associated with this cancer are KRAS, EGFR, IDH, FGFR and BAP 1. Various clinical studies are looking at targeting these genetic mutations. Another therapeutic area of note is the potential for use of immunotherapy in patients with BTC. Although BTC may be a result of chronic inflammation, this does not necessarily translate into increased immunogenicity. This literature review discusses the diverse molecular and immune-related pathways in patients with BTC and their potential therapeutic implications.
Original languageEnglish
Pages (from-to)2623-2642
Number of pages20
JournalCancer Management and Research
Issue number11
Early online date29 Mar 2019
Publication statusPublished - 2019


  • Biliary tract cancer
  • intrahepatic cholangiocarcinoma
  • extrahepatic cholangiocarcinoma
  • gallbladder cancer
  • genome sequencing
  • molecular targets
  • immunotherapy

Research Beacons, Institutes and Platforms

  • Manchester Cancer Research Centre


Dive into the research topics of 'Biliary tract cancers: current knowledge, clinical candidates and future challenges'. Together they form a unique fingerprint.

Cite this